Send to

Choose Destination
Pharmacol Ther. 2014 Feb;141(2):125-39. doi: 10.1016/j.pharmthera.2013.09.004. Epub 2013 Sep 27.

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.

Author information

MedImmune, LLC, Gaithersburg, MD 20878, USA.
Joint Molecular Rheumatology Laboratory of Institute of Health Sciences and Shanghai Renji Hospital, Shanghai, China.
MedImmune, LLC, Hayward, CA 94545, USA.
MedImmune, LLC, Gaithersburg, MD 20878, USA. Electronic address:


Interleukin-6 (IL-6) is a pleiotropic cytokine with significant functions in the regulation of the immune system. As a potent pro-inflammatory cytokine, IL-6 plays a pivotal role in host defense against pathogens and acute stress. However, increased or deregulated expression of IL-6 significantly contributes to the pathogenesis of various human diseases. Numerous preclinical and clinical studies have revealed the pathological roles of the IL-6 pathway in inflammation, autoimmunity, and cancer. Based on the rich body of studies on biological activities of IL-6 and its pathological roles, therapeutic strategies targeting the IL-6 pathway are in development for cancers, inflammatory and autoimmune diseases. Several anti-IL-6/IL-6 receptor monoclonal antibodies developed for targeted therapy have demonstrated promising results in both preclinical studies and clinical trials. Tocilizumab, an anti-IL-6 receptor antibody, is effective in the treatment of various autoimmune and inflammatory conditions notably rheumatoid arthritis. It is the only IL-6 pathway targeting agent approved by the regulatory agencies for clinical use. Siltuximab, an anti-IL-6 antibody, has been shown to have potential benefits treating various human cancers either as a single agent or in combination with other chemotherapy drugs. Several other anti-IL-6-based therapies are also under clinical development for various diseases. IL-6 antagonism has been shown to be a potential therapy for these disorders refractory to conventional drugs. New strategies, such as combination of IL-6 blockade with inhibition of other signaling pathways, may further improve IL-6-targeted immunotherapy of human diseases.


AML; Autoimmune; C-reactive protein; COPD; CRC; CRP; CSC; Cancer; DLT; EAE; EGFR; IBD; IFN; IL-6; IL-6 receptor; IL-6R; Inflammation; Interleukin-6; MM; MS; MTX; Monoclonal antibody; NSCLC; RA; RCC; SJIA; SLE; SOCS; SSc; STAT; TAM; TLR; TNF; Targeted therapy; Toll-like receptor; VEGF; acute myeloid leukemia; cancer stem cells; chronic obstructive pulmonary disease; colorectal cancer; dose-limiting toxicity; epidermal growth factor receptor; experimental autoimmune encephalitis; inflammatory bowel diseases; interferon; interleukin-6; mAb; methotrexate; monoclonal antibody; multiple myeloma; multiple sclerosis; non-small cell lung cancer; renal cell carcinoma; rheumatoid arthritis; sIL-6R; sgp130; signal transducers and activators of transcription; soluble IL-6R; soluble gp130; suppressor of cytokine signaling; systemic juvenile idiopathic arthritis; systemic lupus erythematosus; systemic sclerosis; tumor necrosis factor; tumor-associated macrophage; vascular endothelial growth factor

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center